ITGAX and neoplasm: Therefore, to test the impact of the loss of CD11c+ cells on TRP-2-expressing T cells, we transferred TRP-2 TCR-engineered T cells into tumor-bearing established CD11c.DTR→B6 chimeras and depleted CD11c+ cells by injection of DT from 1 day before until 5 days after T cell transfer (Figure 3A).